In Qatar, laryngeal Cancer is managed by ents. Laryngeal cancer is a malignant tumour of the voice box, in over 95% of cases a squamous cell carcinoma arising from the lining of the glottis (the vocal cords), supraglottis, or subglottis. SEER estimates roughly 12,650 new diagnoses and 3,880 deaths per year in the United States, with a median age at diagnosis of 66 and a 4-to-1 male predominance.
Laryngeal cancer (ICD-10: C32) is a malignant epithelial tumour of the larynx, the cartilaginous voice organ between the pharynx and the trachea. Squamous cell carcinoma accounts for over 95% of cases and is anatomically divided into three subsites with very different biology: glottic cancer (true vocal cords; roughly 60% of cases) presents earliest because even a small lesion changes the voice, supraglottic cancer (epiglottis, false cords, aryepiglottic folds; roughly 30-35%) is associated with heavy alcohol use and lymph node spread, and subglottic cancer (below the cords; under 5%) often presents late with airway obstruction. Field cancerisation from inhaled tobacco carcinogens means second primary tumours of the lung, oral cavity, oropharynx, or oesophagus occur in 10-25% of patients over a lifetime. Staging follows the AJCC 8th edition TNM system, which incorporates depth of invasion, cartilage involvement, vocal cord fixation, and regional nodal disease.
The key symptoms of Laryngeal Cancer are: Persistent hoarseness or voice change lasting more than 3 weeks — the cardinal symptom of glottic cancer, present in over 90% of glottic cases at diagnosis and the trigger for ENT referral in international guidelines., Sore throat that does not resolve over several weeks, often unilateral and worse on swallowing, typical of supraglottic primary tumours., Referred ear pain (otalgia) without otoscopic findings, transmitted via the vagus nerve from a supraglottic or hypopharyngeal lesion — a classic red flag in head and neck oncology., A painless lump in the neck representing metastatic cervical lymphadenopathy, most often the level II/III chain, frequently the presenting sign in supraglottic disease., Progressive difficulty swallowing (dysphagia) for solids, sometimes with food sticking sensation, indicating a bulky supraglottic or post-cricoid lesion., Noisy breathing (stridor) on inspiration or biphasic stridor at rest — a late sign indicating airway compromise that warrants urgent assessment., Chronic dry cough or recurrent throat clearing, sometimes with blood-tinged sputum (haemoptysis) when the tumour ulcerates..
Diagnosis is built on a focused history, full head and neck examination, flexible laryngoscopy in clinic, and tissue biopsy obtained under direct laryngoscopy. NICE NG12 and the American Head & Neck Society recommend urgent ENT referral for any adult with hoarseness lasting over 3 weeks, especially current or former smokers, and any persistent neck lump beyond 3 weeks in adults over 45. Flexible nasendoscopy at the bedside characterises tumour location, extent across subsites, vocal cord mobility (a key staging variable), and airway adequacy. Stroboscopy adds information on mucosal wave and is useful for early glottic lesions. Definitive tissue diagnosis requires biopsy under general anaesthesia at panendoscopy, which simultaneously maps the tumour, screens for synchronous second primaries in the upper aerodigestive tract (occurring in 5-10% of patients), and tattoos the lesion for treatment planning. Cross-sectional imaging — contrast-enhanced CT of the neck and chest, or MRI for soft-tissue and cartilage detail — defines T-stage by documenting cartilage invasion, preepiglottic and paraglottic space involvement, and pre-vertebral extension. Neck ultrasound with fine-needle aspiration evaluates nodal status; FDG-PET/CT is recommended for stage III-IV disease to detect distant metastasis and unknown primaries. Pulmonary function tests and a swallowing assessment are obtained when partial laryngectomy or radiotherapy is being considered. Staging follows the AJCC 8th edition TNM system, and every case is reviewed at a multidisciplinary head and neck oncology meeting before treatment is offered.
Prognosis depends primarily on stage, subsite, and treatment compliance. Five-year relative survival in SEER data is approximately 61% overall, 78% for localised disease, 47% for regional disease, and 34% for distant disease. Glottic cancers carry the best stage-for-stage prognosis because they present early; localised T1 glottic disease has a 5-year survival above 90% with either surgery or radiation. Supraglottic and subglottic primaries do worse due to later presentation and higher nodal involvement. After RTOG 91-11, locally advanced T3 laryngeal cancers treated with concurrent chemoradiation have 10-year overall survival of approximately 28% with 67% larynx preservation; outcomes after total laryngectomy plus adjuvant therapy are broadly similar in survival but commit the patient to a permanent stoma. The two largest modifiable prognostic factors are continued smoking, which roughly doubles the risk of treatment failure and second primaries, and treatment interruption from toxicity or non-compliance. Second primary tumours of the lung, oral cavity, oropharynx, and oesophagus occur in 10-25% of patients over a lifetime and account for many late deaths; lifelong surveillance with cross-sectional imaging and endoscopy is therefore standard.
Any adult with hoarseness lasting more than 3 weeks, persistent unilateral sore throat, referred otalgia with a normal ear exam, a neck lump, or stridor should be referred urgently to ENT (otolaryngology - head and neck surgery), typically through a national 2-week-wait or fast-track pathway. Confirmed laryngeal cancer is managed at a head and neck oncology multidisciplinary centre with surgical, radiation, medical oncology, speech therapy, dietetic, and reconstructive expertise on site. Self-referral or generalist management is associated with worse stage at diagnosis and inferior survival.
Find specialists →Recovery depends on treatment modality. Transoral laser surgery for T1 glottic disease produces 1-2 weeks of mild throat discomfort and full voice recovery within 4-8 weeks. Definitive radiotherapy carries 6-8 weeks of treatment with peak mucositis in weeks 4-6 and gradual recovery over 8-12 weeks; xerostomia, dysphagia, and fatigue can persist beyond 6 months. Concurrent chemoradiation adds neutropenia, ototoxicity, and renal effects; nutritional recovery often takes 6-12 months. Total laryngectomy requires 7-10 days in hospital, voice prosthesis training within 2-4 weeks, and 3-6 months of speech and swallowing rehabilitation. Surveillance every 2-3 months in year 1, every 3-4 months in year 2, every 4-6 months in years 3-5, and annually thereafter follows the NCCN schedule.
Supervised aerobic and resistance exercise during and after head and neck cancer treatment improves fatigue, quality of life, and treatment completion rates. Aim for 150 minutes of moderate-intensity activity per week as tolerated, including 2-3 resistance sessions targeting major muscle groups. Activity should be reduced during acute mucositis or severe fatigue but not stopped entirely. Patients with a tracheostomy or laryngectomy can swim with a Larkel device and otherwise exercise freely with stoma protection in dusty or wet environments.
Choose an ENT consultant or head and neck oncology team that operates within a high-volume multidisciplinary centre (NCCN, ASCO, and NICE all recommend ≥30-50 head and neck cancers per year per centre as a quality threshold). Ask about transoral laser and robotic surgery availability, voice rehabilitation services, tracheoesophageal prosthesis programmes, and the proportion of patients discussed in a documented tumour board. Continuity matters: the same team should follow you through diagnosis, treatment, and 5-year surveillance.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Qatar.
Apply as specialist →Specialists who treat Laryngeal Cancer. Get expert guidance and personalized care.